WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression
- PMID: 18644985
- PMCID: PMC2587040
- DOI: 10.1158/1541-7786.MCR-08-0078
WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression
Abstract
In its role as a tumor suppressor, WT1 transactivates several genes that are regulators of cell growth and differentiation pathways. For instance, WT1 induces the expression of the cell cycle regulator p21, the growth-regulating glycoprotein amphiregulin, the proapoptotic gene Bak, and the Ras/mitogen-activated protein kinase (MAPK) inhibitor Sprouty1. Here, we show that WT1 transactivates another important negative regulator of the Ras/MAPK pathway, MAPK phosphatase 3 (MKP3). In a WT1-inducible cell line that exhibits decreased cell growth and increased apoptosis on expression of WT1, microarray analysis showed that MKP3 is the most highly induced gene. This was confirmed by real-time PCR where MKP3 and other members of the fibroblast growth factor 8 syn expression group, which includes Sprouty 1 and the Ets family of transcription factors, were induced rapidly following WT1 expression. WT1 induction was associated with a block in the phosphorylation of extracellular signal-regulated kinase in response to epidermal growth factor stimulation, an effect mediated by MKP3. In the presence of a dominant-negative MKP3, WT1 could no longer block phosphorylation of extracellular signal-regulated kinase. Lastly, when MKP3 expression is down-regulated by short hairpin RNA, WT1 is less able to block Ras-mediated transformation of 3T3 cells.
Figures





Similar articles
-
MKP3 negatively modulates PDGF-induced Akt and Erk5 phosphorylation as well as chemotaxis.Cell Signal. 2012 Mar;24(3):635-40. doi: 10.1016/j.cellsig.2011.11.001. Epub 2011 Nov 9. Cell Signal. 2012. PMID: 22100392
-
Constitutively active Ras negatively regulates Erk MAP kinase through induction of MAP kinase phosphatase 3 (MKP3) in NIH3T3 cells.BMB Rep. 2014 Dec;47(12):685-90. doi: 10.5483/bmbrep.2014.47.12.017. BMB Rep. 2014. PMID: 24602610 Free PMC article.
-
Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.Carcinogenesis. 2008 Sep;29(9):1742-50. doi: 10.1093/carcin/bgn167. Epub 2008 Jul 16. Carcinogenesis. 2008. PMID: 18632752
-
Negative and positive regulation of MAPK phosphatase 3 controls platelet-derived growth factor-induced Erk activation.J Biol Chem. 2009 Feb 13;284(7):4626-34. doi: 10.1074/jbc.M808490200. Epub 2008 Dec 23. J Biol Chem. 2009. PMID: 19106095
-
Mitogen-activated protein kinase (MAPK) phosphatase 3-mediated cross-talk between MAPKs ERK2 and p38alpha.J Biol Chem. 2011 May 6;286(18):16150-62. doi: 10.1074/jbc.M110.203786. Epub 2011 Mar 16. J Biol Chem. 2011. PMID: 21454500 Free PMC article.
Cited by
-
Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.Nat Rev Cancer. 2011 Feb;11(2):111-21. doi: 10.1038/nrc3002. Epub 2011 Jan 20. Nat Rev Cancer. 2011. PMID: 21248786 Free PMC article. Review.
-
Wilms' tumor 1 (WT1) promotes ovarian cancer progression by regulating E-cadherin and ERK1/2 signaling.Cell Cycle. 2020 Oct;19(20):2662-2675. doi: 10.1080/15384101.2020.1817666. Epub 2020 Sep 7. Cell Cycle. 2020. PMID: 32892698 Free PMC article.
-
Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.J Virol. 2020 Jan 31;94(4):e01837-19. doi: 10.1128/JVI.01837-19. Print 2020 Jan 31. J Virol. 2020. PMID: 31776277 Free PMC article.
-
An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1.Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11154-9. doi: 10.1073/pnas.0901591106. Epub 2009 Jun 22. Proc Natl Acad Sci U S A. 2009. PMID: 19549856 Free PMC article.
-
Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.J Clin Invest. 2010 Nov;120(11):3940-52. doi: 10.1172/JCI44165. Epub 2010 Oct 25. J Clin Invest. 2010. PMID: 20972333 Free PMC article.
References
-
- Rivera MN, Haber DA. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer. 2005;5:699–712. - PubMed
-
- Hosono S, Gross I, English MA, et al. E-cadherin is a WT1 target gene. J Biol Chem. 2000;275:10943–53. - PubMed
-
- Lee SB, Huang K, Palmer R, et al. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell. 1999;98:663–73. - PubMed
-
- English MA, Licht JD. Tumor-associated WT1 missense mutants indicate that transcriptional activation by WT1 is critical for growth control. J Biol Chem. 1999;274:13258–63. - PubMed
-
- Palmer RE, Kotsianti A, Cadman B, et al. WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin. Curr Biol. 2001;11:1805–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous